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Major electrolyte abnormalities are a common toxicity of
cisplatin (Loehrer et al., 1984; Von Hoff et al., 1979; Blachley
et al., 1981; Vogelzang et al., 1985; Dentino et al., 1978).
Chiefly, among those is hypomagnesaemia as first described
by Schilsky and Anderson in 1979 and repeatedly confirmed
(Schilsky et al., 1982; Buckley et al., 1984; Lam & Adelstein,
1986; Stewart et al., 1985), which is thought to occur as a
result of renal tubular magnesium wasting (Safirstein et al.,
1986). The majority of patients affected by hypomagnesaemia
show no signs or symptoms, but its manifestations can in-
clude neuromuscular irritability, weakness, confusion,
seizures and ventricular arrhythmias (Vallee et al., 1960;
Winkler et al., 1979; Willox et al., 1986). Therefore,
hypomagnesaemia represents a potentially serious condition.
Magnesium aspartate hydrochloride (MgAH) (Magnesio-
card, Ciba-Geigy, Summit, NJ, USA) is a magnesium com-
pound designed for oral administration in the treatment of
magnesium deficiency. The intent of this randomised trial
was to determine if MgAH is able to prevent and/or
replenish the cisplatin-induced loss of body stores of
magnesium.
Eligible patients had a histological diagnosis of locally
advanced cancer of the head and neck. All patients were
previously untreated, and had a performance status of <2
(CALGB). Signed informed consent was obtained from all
patients. The treatment plan called for patients to receive
three or four cycles of cisplatin-based neoadjuvant chemo-
therapy (Vokes et al., 1989, 1990). Entry CBC and serum
chemistries were required to be within normal limits (serum
magnesium > 1.6 mg dl-', 24 h creatinine clearance > 50
cm3min-'). Patients who had severe and/or persistent diarr-
hoea, a serum albumin of <2.5 g dl-' or a recent history of
use of magnesium containing antacids, laxatives or vitamins
were ineligible for study.
Neoadjuvant chemotherapy consisted of methotrexate
120mgm-' given on day 1, followed 24h later by cisplatin
100 mg m-2 given as a 6 h intravenous infusion and a 5 day
continuous infusion of 5-FU at 1,000 mg m-2day-'. Leuco-
vorin rescue was given at 25 mg m-2 every 6 h for 6 doses on
days 2 and 3 (Vokes et al., 1989). For some patients chemo-
therapy consisted of cisplatin 20 mg m-2 administered over
2h on days 1-5 (total dose 100mgm-2 per cycle), bleo-
mycin 10 mg m-2 day-' administered as a continuous
infusion on days 3-7 and methotrexate 200 mgm-2 days 14
and 21 with leucovorin rescue on days 15 and 22 for cycles 1
and 3. For cycles 2 and 4, these patients received 100mg m-2
ofcisplatin on day 1 followed by a 5-day continuous infusion
of 5-FU at 1,000mg m-2 day-' (Vokes et al., 1990). Stan-
dard anti-emetic and hydration schedules for cisplatin were
administered. Cycles were repeated every 3-4 weeks. The
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cisplatin dose was modified according to the 24 h creatinine
clearance obtained before,each cycle ofchemotherapy (30-50
cm3 min-'; 50% of calculated dose; <30cm3 min- ; no cis-
platin administered).
To evaluate the efficacy of MgAH, patients were ran-
domised into two groups: group A received oral MgAH
replacement on a continuous basis throughout all cycles of
neoadjuvant chemotherapy; group B received oral MgAH
intermittently whenever their serum magnesium level
decreased to < 1.4 mg dl-' and continued MgAH until
recovery of serum magnesium levels to 1.8 mg dl-' or
greater.
For patients in group A, replacement doses of MgAH were
started on day 1 of chemotherapy at a dose of 10 mEq p.o.
administered three times daily on the day of initiating the
first chemotherapy cycle. Patients in group A whose serum
magnesium fell below < 1.4 mg dl-' despite continuous oral
MgAH had their dose of MgAH increased to 20 mEq three
times daily. If hypomagnesaemia was not corrected within 3
weeks, alternative therapy was not specified by the protocol,
but usually consisted of continuation of 20 mEq of MgAH or
the administration of additional parenteral magnesium sul-
phate. If the serum magnesium level exceeded 2.5 mg dl-' or
severe gastrointestinal side-effects occurred, the MgAH
dosage was decreased. Supplementation continued through-
out the entire duration of treatment with neoadjuvant
chemotherapy (3-4 months).
Patients in group B initially received no MgAH replace-
ment and were followed clinically as described for group A.
When patients developed hypomagnesaemia < 1.4 mg dl-'
MgAH was started at 10 mEq p.o. three times daily. If serum
magnesium levels did not reach 1.4 mg dl-' within 3 weeks,
the dose was increased to 20 mEq of MgAH. Magnesium
supplementation in group B was discontinued whenever
serum magnesium levels reached 1.8 mg dl-' or greater.
At study entry and before each cycle of chemotherapy the
following laboratory tests were obtained: serum electrolytes
and magnesium, renal and liver function tests, and a 24 h
urine for total volume, creatinine clearance, calcium,
magnesium, sodium and potassium. On day 7 of each cycle
the serum BUN, creatinine, magnesium, calcium, potassium
and sodium were determined. Patient compliance was
assessed on both study arms by counting the number of
returned MgAH doses at the end of each cycle.
Comparability of the two randomised groups for present-
ing patient characteristics was assessed by the Fisher exact
test (Siegel, 1956) for 2 x 2 tables and the Wilcoxon rank
sum test (Snedecor & Cochran, 1980) for continuous data.
Comparisons of the randomised groups by treatment cycle
for magnesium dosage and serum magnesium levels was per-
formed by the Wilcoxon rank sum test. Significance was set a
0.05 and all tests performed were two-sided.
Twenty-three patients were entered and randomized to
treatment on this study. There were no significant differences
between the randomised groups with respect to sex, age and
serum chemistries at the time of study entry.
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Five patients in this trial did not complete all cycles of
neoadjuvant therapy: three developed chemotherapy-related
complications (neutropenic fever and sepsis, severe mucos-
itis), one refused further chemotherapy after cycle 3, and one
patient expired suddenly at home following cycle 3, presum-
ably of acute myocardial infarction. Therefore, the number
of patients included in the subsequent analyses reflects the
decreasing size of the patient cohort as the study progressed.
Thirteen patients randomised to group A received MgAH
throughout the entire duration of the administration of neo-
adjuvant chemotherapy. Ten patients randomised to group B
were to receive MgAH only when their serum magnesium fell
to A 1.4 mg dl and this was to be discontinued when it
reached or exceeded 1.8 mg dl-'. As shown in Table I, during
the first two cycles of chemotherapy many patients on the
intermittent arm had initial magnesium levels that did not
require MgAH therapy (80% cycle 1 and 44% cycle 2). By
the third cycle, however, virtually all patients in group B still
on-study (89%) required MgAH and on the fourth cycle
86% required MgAH. All patients on the intermittent arm
required MgAH at some point during their therapy. Addi-
tionally, of the nine patients who received at least two cycles
of cisplatin therapy, seven (78%) had no discontinuation in
MgAH therapy once it had been introduced into their
therapy program.
Similarly, the difference in the dose of MgAH administered
to patients on each arm was statistically significant only
during cycle 1 (Table I). By cycle 3 the actual MgAH dose
administered to patients in both arms of this study was very
similar, reflecting the fact that by cycle 3 most patients in
group B were actually receiving MgAH. It is of note that no
patient developed side-effects related to administration of
MgAH, and diarrhoea in particular was not observed.
Serum magnesium levels were determined before each cycle
of cisplatin-based chemotherapy and on day 7 (Table II).
Only patients who received all four cycles of cisplatin and
had all serum magnesium levels obtained are included in this
analysis. Median magnesium levels in both groups were
higher immediately before cisplatin administration compared
to those on day 7 for all four cycles, indicating at least
partial recovery of hypomagnesaemia with increasing time
from cisplatin administration. There may also be a slight
decrease in pre-cisplatin magnesium levels over time. The
median magnesium concentrations were always lower in
Table I Dosage of MgAH in mEq by cycle of cisplatin
Continuous Intermittent Wilcoxon
MgAH MgAH P-value
Cycle 1
No. on-study 13 10
No. treated 13 (100%) 2 (20%)
Median dosage 190 0 0.0004
(range) (110-290) (0-200)
Cycle 2
No. on-study 12 9
No. treated 12 (100%) 5 (56%)
Median dosage 680 200 0.06
(range) (500-1600) (0- 1420)
Cycle 3
No. on-study 11 9
No. treated 11 (100%) 8 (89%)
Median dosage 680 460 0.32
(range) (210- 1610) (0- 1580)
Cycle 4
No. on-study 10 7
No. treated 10 (100%) 6 (86%)
Median dosage 735 570 0.20
(range) (490- 1460) (0- 1550)
Summary
No. on-study 13 10
No. ever received MgAH 13 (100%) 10 (100%)
TableII Serummagnesiumlevelsbycycleofcisplatinand randomised
arm
Continuous MgAH Intermittent MgAH
(n = 10) (n = 7)
Median Median
(range) (range)
Cycle I
Pre-cycle 2.1 1.9
(1.7-2.5) (1.6-2.2)
Day 7 1.7 1.5
(1.2-2.1) (1.3-1.7)
Cycle 2
Pre-cycle 2.0 1.7
(1.7-2.5) (1.2-2.1)
Day 7 1.6 1.4
(1.0-2.2) (1.2-1.6)
Cycle 3
Pre-cycle 1.8 1.7
(1.4-2.7) (1.2-2.4)
Day 7 1.8 1.4
(1.1-2.1) (1.2-1.9)
Cycle 4
Pre-cycle 1.8 1.7
(1.4-2.2) (1.4-2.3)
Day 7 1.7 1.3
(1.1-2.3) (0.9-1.7)
Onlypatientscompletingallplannedcyclesofchemotherapywhohad
all planned serum magnesium determinations are included in this
analysis.
group B than in group A, but this difference was not statis-
tically significant.
Since severe hypomagnesaemia can lead to clinically
significant morbidity we analysed frequency of hypomagnes-
aemia <1.4mg dl-' or <1.0mg dl-'. Hypomagnesaemia
<1.4mg dl-' was observed in 10 of 44 cycles in group A
and 11 of 35 cycles in group B. There were only two
documentations of a magnesium level <1.0 mg dl- which
occurred in a patient in group B during cycle 4 and in a
patient in group A, who suffered from neutropenic sepsis and
received multiple intravenous infusions while in intensive
care. Severe hypomagnesaemia <1.0 mg dl-' may therefore
have been largely prevented by the administration of MgAH
on both arms of this study.
These results confirm a high incidence of hypomagnes-
aemia in cisplatin-treated patients and its relation to the
cumulative cisplatin dose. By the final cycle of neoadjuvant
chemotherapy, all patients had documented episodes of
hypomagnesaemia. This finding is further substantiated by
the fact that by cycle 3 virtually all patients in the control
group required continuous MgAH replacement. It is clear
that with this replacement and the repeated monitoring of
serum Mg2 + concentrations, severe hypomagnesaemia epi-
sodes (< 1.0 mg dl-') were rare and no patient in this study
experienced clinical symptoms related to hypomagnesaemia.
Moderate hypomagnesaemia < 1.4 mg dl-' was documented
more frequently, although only 20% of patients receiving
continuous MgAH developed hypomagnesaemia in a given
cycle. This does suggest that preventive administration of a
magnesium supplement can ameliorate, if not completely
eradicate, cisplatin-induced hypomagnesaemia.
While severe hypomagnesaemia was infrequent on both
arms of this study, we recommend the continuous schedule
for clinical practice, since virtually all patients randomised to
intermittent MgAH eventually required continuous magnes-
ium supplementation. The specific magnesium compound
used in this study is not commercially available in the United
States. However, other magnesium compounds may be of
similar efficacy and should be evaluated in future studies.
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